• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA. The company engages in manufacture, development and commercialization of products derived from its proprietary technology for use in treating human diseases. The company was founded on 9th, November 1981 and is headquartered in Waltham, MA.
Market Cap | 477.47 Million | Shares Outstanding | 34.725 Million | Avg 30-day Volume | 1.378 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.83 |
Price to Revenue | 1.0747 | Debt to Equity | 1.1301 | EBITDA | -151.707 Million |
Price to Book Value | 1.2748 | Operating Margin | -72.2687 | Enterprise Value | 446.801 Million |
Current Ratio | 1.75 | EPS Growth | 0.211 | Quick Ratio | 1.46 |
1 Yr BETA | 0.9802 | 52-week High/Low | 0.0 / | Profit Margin | -75.2418 |
Operating Cash Flow Growth | 79.4121 | Altman Z-Score | -1.8895 | Free Cash Flow to Firm | 32.269 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
No longer subject to file | 2020-11-16 | 0 | |
|
No longer subject to file | 2020-11-16 | 0 | |
|
No longer subject to file | 2020-11-16 | 0 | |
MYERS SCOTT DUNSETH PRESIDENT & CEO |
|
No longer subject to file | 2020-11-16 | 0 |
VITTIGLIO JOSEPH CHIEF BUSINESS OFFICER, GC |
|
No longer subject to file | 2020-11-16 | 0 |
|
No longer subject to file | 2020-11-16 | 0 | |
|
No longer subject to file | 2020-11-16 | 0 | |
|
No longer subject to file | 2020-11-16 | 0 | |
|
No longer subject to file | 2020-11-16 | 0 | |
|
No longer subject to file | 2020-11-16 | 0 | |
CASCIANO ANTHONY CHIEF OPERATING OFFICER |
|
No longer subject to file | 2020-11-16 | 0 |
|
No longer subject to file | 2020-11-16 | 0 | |
SCHICK KELLY CHIEF HUMAN RESOURCES OFFICER |
|
No longer subject to file | 2020-11-16 | 0 |
PIEKOS BRIAN CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2020-11-16 | 0 |
|
0 | 2020-10-01 | 0 | |
|
4,468,000 | 2020-03-16 | 0 | |
MYLES EDWARD H COO & CFO |
|
98,659 | 2020-03-10 | 0 |
HEIDEN WILLIAM K PRESIDENT & CEO |
|
424,612 | 2020-03-02 | 0 |
KROP JULIE CHIEF MEDICAL OFFICER |
|
73,044 | 2020-03-02 | 0 |
|
5,000 | 2019-09-04 | 0 | |
|
3,499,428 | 2019-08-12 | 0 | |
|
33,629 | 2019-05-16 | 0 | |
|
26,354 | 2019-05-16 | 0 | |
BOLGIANO ELIZABETH SCOTT CHIEF HUMAN RESOURCES OFFICER |
|
74,847 | 2019-05-09 | 0 |
BUTCHER JAMES ALAN EVP, CHIEF BUSINESS OFFICER |
|
50,628 | 2019-04-30 | 0 |
GRUND NICHOLAS CHIEF COMMERCIAL OFFICER |
|
84,805 | 2019-03-02 | 0 |
|
24,913 | 2018-06-07 | 0 | |
|
5,571 | 2017-05-18 | 0 | |
THOMAS FRANK E PRESIDENT & COO |
|
138,195 | 2017-02-23 | 0 |
WILSON KENNETH H SVP, SALES AND MARKETING |
|
23,387 | 2015-12-02 | 0 |
CROUSE GEOFFREY EVP |
|
18,750 | 2015-08-31 | 0 |
HOLMES SCOTT A SVP, FINANCE AND TREASURER |
|
51,958 | 2015-06-15 | 0 |
TOWNSEND SCOTT B SVP, GENERAL COUNSEL |
|
56,851 | 2015-03-03 | 0 |
JORDAN EDWARD P. SVP, SALES AND MARKETING |
|
39,213 | 2015-03-03 | 0 |
|
No longer subject to file | 2015-01-07 | 0 | |
CAFFE STEVEN SVP, CH. DEV. AND REG. OFFICER |
|
59,400 | 2014-08-19 | 0 |
WHITE CHRISTOPHER G CHIEF BUSINESS OFFICER |
|
28,400 | 2014-02-27 | 0 |
|
23,900 | 2013-05-23 | 0 | |
MADISON GREG EVP, CHIEF COMMERCIAL OFFICER |
|
18,800 | 2013-02-28 | 0 |
ALLEN LEE F MD PHD EVP, CHIEF MEDICAL OFFICER |
|
2,229 | 2012-08-06 | 0 |
|
14,822 | 2012-05-24 | 0 | |
|
0 | 2012-05-23 | 0 | |
FARMER JOSEPH L GENERAL COUNSEL, SVP |
|
0 | 2012-02-24 | 0 |
ZIEZIULA GARY J EVP, CHIEF COMMERCIAL OFFICER |
|
2,500 | 2011-07-29 | 0 |
ENGLISH EDWARD C VP, CONTROLLER, INTERIM CFO |
|
88 | 2011-06-24 | 0 |
ARKOWITZ DAVID EVP, CFO, CBO |
|
1,806 | 2011-05-31 | 0 |
|
0 | 2011-05-24 | 0 | |
PEREIRA BRIAN JG PRESIDENT AND CEO |
|
5,000 | 2011-03-01 | 0 |
ZAYAS RICARDO SVP, OPERATIONS |
|
0 | 2011-01-07 | 0 |
HEALEY TIMOTHY G SVP, COMMERCIAL OPERATIONS |
|
0 | 2010-02-24 | 0 |
|
0 | 2008-12-19 | 0 | |
|
0 | 2008-12-19 | 0 | |
LEWIS JEROME M SVP OF SCIENTIFIC OPERATIONS |
|
0 | 2008-08-05 | 0 |
BRENNER LOUIS MD SENIOR VICE PRESIDENT |
|
36,500 | 2007-11-12 | 0 |
GOLDSTEIN JEROME EXEC. CHAIRMAN & TREASURER |
|
420,504 | 2007-04-16 | 0 |
AVALLONE MICHAEL N VP - FINANCE & CFO |
|
4,250 | 2007-02-02 | 0 |
BLOCH SHELDON L |
|
68,973 | 2006-11-27 | 0 |
|
3,834 | 2006-11-07 | 0 | |
STEINMAN THEODORE I |
|
3,834 | 2006-11-07 | 0 |
|
413,918 | 2006-03-21 | 0 | |
|
1,028,733 | 2006-01-12 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|